Scholar Rock Holding Corp. (SRRK)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Scholar Rock Holding Corp. (SRRK)
Company Performance

Current Price

as of Oct 16, 2024

$29.00

P/E Ratio

N/A

Market Cap

$2.62B

Description

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

Metrics

Overview

  • HQCambridge, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerSRRK
  • Price$29+1.61%

Trading Information

  • Market Cap$2.62B
  • Float83.17%
  • Average Daily Volume (1m)4,145,261
  • Average Daily Volume (3m)1,795,159
  • EPS-$2.33

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$58.51M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$59.00M
  • EV$684.00M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B17.36
Documents
SEC Filings
8-K (2024-10-10)
8-K (2024-10-07)
8-K (2024-08-08)
8-K (2024-06-28)
8-K (2024-06-24)
8-K (2024-06-03)
8-K (2024-05-22)
8-K (2024-05-14)
8-K (2024-05-07)
8-K (2024-03-19)
8-K (2024-02-15)
8-K (2024-01-08)
8-K (2023-11-07)
8-K (2023-10-12)
8-K (2023-10-11)
8-K (2023-08-09)
8-K (2023-06-30)
8-K (2023-06-22)
8-K (2023-05-09)
8-K (2023-04-10)
8-K (2023-03-13)
8-K (2023-03-07)
8-K (2023-01-09)
10-Q (2024-08-08)
10-Q (2024-05-07)
10-Q (2023-11-07)
10-Q (2023-08-09)
10-Q (2023-05-09)
10-K (2024-03-19)
10-K (2023-03-07)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2023Q3
Earnings Report (2023-11-07)
Earnings Report (2020-08-12)
Factset
Factset Business Description
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Scholar Rock Q3 (2023-11-08T09:13:31Z)
Scholar Rock upgraded to buy from hold at Jefferies ($7.65, 0.00) (2023-10-30T18:01:46Z)
Scholar Rock reports Q3 EPS ($0.53) vs FactSet ($0.50) [8 est, ($0.57)-(0.39)] - 8-K ($12.17, 0.00) (2023-11-07T12:19:29Z)
Scholar Rock announces presentation of new data from phase 1 DRAGON trial of SRK-181 at SITC ($12.44, 0.00) (2023-11-03T20:03:57Z)
Scholar Rock 12.4M-share secondary priced at $6.85/share through JPMorgan, Piper Sandler ($6.85, 0.00) (2023-10-30T18:01:51Z)
Insider transaction: Scholar Rock holder Samsara BioCapital discloses purchase of 2.2M shares - Form 4 ($7.52, 0.00) (2023-10-30T18:01:49Z)